{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:57:48Z","timestamp":1756382268455,"version":"3.44.0"},"reference-count":31,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:p>When we reviewed the management of open-angle glaucoma in 1997,1 the topical drug treatments available included beta-blockers, a carbonic anhydrase inhibitor (dorzolamide), an alpha<jats:sub>2<\/jats:sub> agonist (apraclonidine), a prostaglandin analogue (latanoprost) and a variety of miotics and sympathomimetics. We concluded that a beta-blocker was the treatment of first choice. Here, we review seven new topical preparations that have been marketed, or had their licensed indications changed, since our earlier article.<\/jats:p>","DOI":"10.1136\/dtb.2003.41212","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"12-14","source":"Crossref","is-referenced-by-count":3,"title":["New topical drugs for open-angle glaucoma"],"prefix":"10.1136","volume":"41","member":"239","published-online":{"date-parts":[[2003,2,1]]},"reference":[{"key":"2025082702531781000_41.2.12.1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/dtb.1997.3514","article-title":"The management of primary open angle glaucoma","volume":"35","year":"1997","journal-title":"DTB"},{"key":"2025082702531781000_41.2.12.2","first-page":"5","article-title":"Blindness and partial sight in England and Wales: April 1990 - March 1991","volume":"28","author":"Evans","year":"1996","journal-title":". Health Trends"},{"key":"2025082702531781000_41.2.12.3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.4","DOI":"10.1001\/archopht.120.6.701"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.5","DOI":"10.1001\/archopht.120.10.1268"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.6","DOI":"10.1016\/S0002-9394(00)00538-9"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.7","DOI":"10.1016\/S0002-9394(98)00095-6"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.8","DOI":"10.1016\/S0002-9394(99)00343-8"},{"key":"2025082702531781000_41.2.12.9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9394(01)00974-6","article-title":"Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension","volume":"132","author":"Michaud","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"2025082702531781000_41.2.12.10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9394(98)00438-3","article-title":"Irreversible corneal decompensation in patients treated with topical dorzolamide","volume":"127","author":"Konowal","year":"1999","journal-title":"Am J Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.11","DOI":"10.1016\/S0002-9394(98)00438-3"},{"key":"2025082702531781000_41.2.12.12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","article-title":"Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients","volume":"127","author":"Katz LJ and the Bromonidine Study Group","year":"1999","journal-title":"Am J Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.13","DOI":"10.1016\/S0002-9394(98)00286-4"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.14","DOI":"10.1016\/S0002-9394(01)00834-0"},{"key":"2025082702531781000_41.2.12.15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00061198-200204000-00003","article-title":"Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study","volume":"11","author":"Kampik","year":"2002","journal-title":"J Glaucoma"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.16","DOI":"10.1097\/00061198-200204000-00003"},{"key":"2025082702531781000_41.2.12.17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bjo.85.8.983","article-title":"Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension","volume":"85","author":"Zhang","year":"2001","journal-title":"Br J Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.18","DOI":"10.1136\/bjo.85.8.983"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.19","DOI":"10.1136\/bjo.84.6.579"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.20","DOI":"10.1016\/S0149-2918(00)83048-9"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.21","DOI":"10.1016\/S0002-9394(00)00902-8"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.22","DOI":"10.1016\/S0149-2918(01)80150-8"},{"key":"2025082702531781000_41.2.12.23","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"2025082702531781000_41.2.12.24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02850299","article-title":"Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension","volume":"18","author":"Gandolfi","year":"2001","journal-title":"Adv Ther"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.25","DOI":"10.1007\/BF02850299"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.26","DOI":"10.1016\/S0002-9394(02)01827-5"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.27","DOI":"10.1016\/S0002-9394(01)01177-1"},{"doi-asserted-by":"publisher","key":"2025082702531781000_41.2.12.28","DOI":"10.1097\/00061198-200110000-00010"},{"key":"2025082702531781000_41.2.12.29","first-page":"191","article-title":"Histological effects in the iris after 3 months of latanoprost therapy. The Mainz 1 Study","volume":"119","author":"Pfeiffer","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"2025082702531781000_41.2.12.30","first-page":"17","article-title":"A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide","volume":"106","author":"Clineschmidt","year":"1999","journal-title":"Ophthalmol"},{"key":"2025082702531781000_41.2.12.31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00417-002-0553-0","article-title":"A comparison of the fixed combination of latanoprost and timolol with its individual components","volume":"240","author":"Pfeiffer","year":"2002","journal-title":"Graefe's Arch Clin Exp Ophthalmol"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2003.41212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:53:25Z","timestamp":1756288405000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2003.41212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2003,2,1]]},"published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1136\/dtb.2003.41212"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2003.41212","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}